TP53 and head and neck squamous cell carcinoma: Of note, all of stage I/II patients (5 patients) had wild-type TP53, and patients with a past history of HNSCC or ESCC were significantly greater in the TP53 mutation groups than in the wild-type groups (P = 0.02).